X

Trial Profile

A Multicenter, Open-label Phase I/II Study of XZP-3287 in Metastasis Solid Tumors in China

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Birociclib (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Sihuan Pharmaceutical Holdings Group

Most Recent Events

08 Sep 2024 Planned End Date changed from 30 Dec 2022 to 31 Dec 2025.
08 Sep 2024 Status changed from recruiting to active, no longer recruiting.
24 Oct 2023 Results (n=131) assessing efficacy and safety of birociclib in patients with refractory metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com